Dual‐Targeted Nanoreactors and Prodrugs: Hydrogen Peroxide Triggers Oxidative Damage and Prodrug Activation for Synergistic Elimination of Cancer Cells
Source abstract
Abstract
Abstract Synergistic strategies by combining nanoreactors and prodrugs hold tremendous potential in anticancer treatment. However, precise death of target cancer cells remains a significant challenge due to the absence of an elaborate cancer targeting strategy. Here, a dual‐targeting approach that combines the action of H2O2‐producing folate receptor‐targeted nanoreactors with a cyclooxygenase‐2 (COX‐2) targeted prodrug is reported. A folate‐modified silica nanoreactor encapsulating glucose oxidase (GOX) is prepared to generate H2O2, which induces oxidative stress and allows the activation of the prodrug by targeted intracellular delivery. A novel prodrug bearing both COX‐2 targeting Celecoxib and SN‐38 anticancer agent with an H2O2‐cleavable thioketal linker to activate the drug is presented. By dual‐targeting, the generated H2O2 from GOX triggers the cleavage of a thioketal linker in the prodrug to produce the active form of the SN‐38 anticancer drug in cancer cells inducing synergistic cell death. This dual‐targeting strategy with a synergistic potency can aid in developing selective and effective anticancer therapeutics.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Synthesis and Catalytic Reactions · Enzyme function and inhibition
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Physical Chemistry of Polymers Max Planck Institute for Polymer Research Ackermannweg 10 55128 Mainz Germany
Department of Chemistry Korea University Seoul 02841 Republic of Korea
Sustainable Polymer Chemistry Group MESA+ Institute for Nanotechnology Faculty of Science and Technology Universiteit Twente PO Box 217 Enschede 7500 Netherlands
Funding
National Research Foundation of Korea
References (70)
Show source-provided references
1. 10.1002/adhm.20180162710.1002/adhm.201801627 ↗
2. 10.1016/j.biomaterials.2019.01.00310.1016/j.biomaterials.2019.01.003 ↗
3. 10.1016/j.jconrel.2019.04.03210.1016/j.jconrel.2019.04.032 ↗
4. 10.1038/s41467-018-07197-810.1038/s41467-018-07197-8 ↗
5. 10.1158/1078-0432.CCR-16-308310.1158/1078-0432.CCR-16-3083 ↗
6. 10.3390/molecules2522529410.3390/molecules25225294 ↗
7. Mahfoozur R. · Curr. Top. Med. Chem. · 2017 · 17 · 162
8. 10.1080/17425247.2020.176256510.1080/17425247.2020.1762565 ↗
9. 10.1002/anie.20180137810.1002/anie.201801378 ↗
10. 10.1002/adma.20180832510.1002/adma.201808325 ↗
11. 10.1002/adtp.20200011010.1002/adtp.202000110 ↗
12. 10.1002/smll.20190389510.1002/smll.201903895 ↗
13. 10.1021/acs.nanolett.9b0426310.1021/acs.nanolett.9b04263 ↗
14. 10.1021/acsnano.9b0246610.1021/acsnano.9b02466 ↗
15. 10.1002/anie.20161068210.1002/anie.201610682 ↗
16. 10.1039/D0MH00105H10.1039/D0MH00105H ↗
17. 10.1021/acs.nanolett.7b0353110.1021/acs.nanolett.7b03531 ↗
18. 10.1016/j.biomaterials.2018.02.00410.1016/j.biomaterials.2018.02.004 ↗
19. 10.1002/smll.20200089710.1002/smll.202000897 ↗
20. 10.1039/C8CC03599G10.1039/C8CC03599G ↗
21. 10.1038/s41467-019-09566-310.1038/s41467-019-09566-3 ↗
22. 10.1039/D0TB02510K10.1039/D0TB02510K ↗
23. 10.1021/jacs.9b0717110.1021/jacs.9b07171 ↗
24. 10.1002/anie.20201268710.1002/anie.202012687 ↗
25. 10.1021/acsabm.0c0044310.1021/acsabm.0c00443 ↗
26. 10.1039/C6OB00493H10.1039/C6OB00493H ↗
27. 10.1002/cmdc.20130035510.1002/cmdc.201300355 ↗
28. 10.1016/j.biomaterials.2018.09.00610.1016/j.biomaterials.2018.09.006 ↗
29. 10.1039/C7SC04004K10.1039/C7SC04004K ↗
30. Campbell I. G. · Cancer Res. · 1991 · 51 · 5329
31. 10.1093/annonc/mdv25010.1093/annonc/mdv250 ↗
32. 10.1021/acsami.0c0200610.1021/acsami.0c02006 ↗
33. 10.1054/mehy.2000.140610.1054/mehy.2000.1406 ↗
34. 10.1006/bbrc.1999.020810.1006/bbrc.1999.0208 ↗
35. 10.1158/0008-5472.CAN-04-064810.1158/0008-5472.CAN-04-0648 ↗
36. 10.1016/j.febslet.2006.12.02010.1016/j.febslet.2006.12.020 ↗
37. 10.1254/jjp.79.3310.1254/jjp.79.33 ↗
38. 10.1016/j.molcel.2007.03.01610.1016/j.molcel.2007.03.016 ↗
39. Wallin Å. · Oncol. Rep. · 2008 · 19 · 1493
40. 10.1002/bmc.134510.1002/bmc.1345 ↗
41. 10.1002/adfm.20180070610.1002/adfm.201800706 ↗
42. 10.1002/adfm.20190771610.1002/adfm.201907716 ↗
43. 10.1021/acsami.8b1119810.1021/acsami.8b11198 ↗
44. 10.1021/acsami.0c0558810.1021/acsami.0c05588 ↗
45. 10.1002/anie.20201202310.1002/anie.202012023 ↗
46. 10.1110/ps.0468820410.1110/ps.04688204 ↗
47. 10.3402/nano.v3i0.1849610.3402/nano.v3i0.18496 ↗
48. 10.1002/advs.20180186810.1002/advs.201801868 ↗
49. 10.1002/smll.20200330910.1002/smll.202003309 ↗
50. 10.1021/acsami.0c1223710.1021/acsami.0c12237 ↗
51. 10.1016/j.aca.2010.07.00410.1016/j.aca.2010.07.004 ↗
52. 10.1016/j.ajps.2017.11.00210.1016/j.ajps.2017.11.002 ↗
53. 10.1021/acs.biomac.9b0062810.1021/acs.biomac.9b00628 ↗
54. Lee S. H. · Adv. Funct. Mater. · 2013 · 2 · 908
55. 10.1021/acsami.8b0826910.1021/acsami.8b08269 ↗
56. 10.1021/acsnano.7b0821910.1021/acsnano.7b08219 ↗
57. 10.2174/138945011966618080312173710.2174/1389450119666180803121737 ↗
58. 10.1016/j.dyepig.2017.11.05310.1016/j.dyepig.2017.11.053 ↗
59. Ke W. · ACS Nano · 2019 · 13 · 2357
60. 10.1038/srep2901810.1038/srep29018 ↗
61. 10.1016/j.nano.2015.03.00410.1016/j.nano.2015.03.004 ↗
62. 10.1039/b803601b10.1039/b803601b ↗
63. 10.1016/j.tiv.2008.02.00310.1016/j.tiv.2008.02.003 ↗
64. 10.1093/clinchem/33.2.21410.1093/clinchem/33.2.214 ↗
65. 10.1016/0891-5849(94)00217-810.1016/0891-5849(94)00217-8 ↗
66. 10.1021/acs.analchem.7b0533710.1021/acs.analchem.7b05337 ↗
67. 10.1158/0008-5472.CAN-10-426110.1158/0008-5472.CAN-10-4261 ↗
68. 10.1016/j.cell.2015.08.01210.1016/j.cell.2015.08.012 ↗
69. 10.1021/acs.nanolett.1c0189410.1021/acs.nanolett.1c01894 ↗
70. 10.1002/prp2.14910.1002/prp2.149 ↗